PRODIGY BIOTECH, INC.

Biotech · Private

Avian IgY antibodies targeting Candida albicans and candidalysin for alcohol-associated hepatitis treatment

Grants
$314K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Investigation of Novel IgY Technology for Fungal Targets in Alcohol-associated Hepatitis$314,363
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2265LineaGen, Inc—$38M
2266GPER G-1 Development Group LLC——
2267VIROGENICS, INC.——
2268PRODIGY BIOTECH, INC.——
2269PranaX Corp—$10M
2270Lilac Therapeutics——
2271IMMUNYX PHARMA USA INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Aquatic Feed Pellets And Method Of Preparationapplication
  • Formulations For Oral Delivery Of Polypeptides, Antibodies And Proteins And Uses Thereofapplication
  • Aquatic Feed Pellets And Method Of Preparationapplication
  • Formulations For Oral Delivery Of Polypeptides, Antibodies And Proteins And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.